Novartis AG Common Stock (NVS)

(BPT) - What is it like for millions of American families managing food allergies? To better understand these experiences, Genentech, a member of the Roche Group, and the Novartis Pharmaceuticals Corporation partnered with The Harris Poll to survey U.S. parents and guardians of children with food allergies. Explore the findings in this infographic to uncover the impact of food allergies and how increased awareness, education, and support can help affected families. If you or your child have food allergies, schedule an appointment with an allergist to discuss your options.

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout.

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced.

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.